Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials.

AML secondary trials

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
11 Nov 2020
Historique:
received: 11 10 2020
revised: 05 11 2020
accepted: 08 11 2020
entrez: 14 11 2020
pubmed: 15 11 2020
medline: 15 11 2020
Statut: epublish

Résumé

We report the outcomes of secondary acute myeloid leukemia (s-AML) patients included in one of 13 European Organisation for Research and Treatment of Cancer (EORTC) collaborative AML trials using intensive remission-induction chemotherapy. Among 8858 patients treated between May 1986 and January 2008, 960 were identified as having s-AML, either after MDS (cohort A;

Identifiants

pubmed: 33187229
pii: cancers12113334
doi: 10.3390/cancers12113334
pmc: PMC7697114
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Fondation contre le Cancer
ID : grant to EORTC
Organisme : Fonds De La Recherche Scientifique - FNRS
ID : FB Senior research associate mandate

Références

Blood. 2001 Oct 15;98(8):2326-31
pubmed: 11588026
Blood Adv. 2017 Jul 19;1(17):1312-1323
pubmed: 29296774
Br J Haematol. 2020 Feb;188(3):428-437
pubmed: 31612473
JAMA Oncol. 2017 Jul 1;3(7):936-943
pubmed: 28152123
Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5401-10
pubmed: 25516983
Blood Adv. 2018 Aug 28;2(16):2127-2135
pubmed: 30143527
N Engl J Med. 2010 Nov 25;363(22):2091-101
pubmed: 21105791
Leuk Res. 2018 Jun 1;70:91-96
pubmed: 29908418
Leukemia. 2014 Feb;28(2):289-92
pubmed: 23760400
Ann Hematol. 2016 Jan;95(2):191-9
pubmed: 26596971
J Clin Oncol. 2014 Jan 20;32(3):219-28
pubmed: 24297940
Am J Hematol. 2015 Mar;90(3):208-14
pubmed: 25421221
J Clin Oncol. 2009 Nov 10;27(32):5397-403
pubmed: 19826132
N Engl J Med. 1995 Jan 26;332(4):217-23
pubmed: 7808487
Haematologica. 2019 Jun;104(6):1168-1175
pubmed: 30523055
Ann Hematol. 2012 Jun;91(6):825-35
pubmed: 22460947
Ann Hematol. 2015 Dec;94(12):1981-9
pubmed: 26410352
Leukemia. 1995 Nov;9(11):1805-11
pubmed: 7475266
J Clin Oncol. 2013 Dec 10;31(35):4424-30
pubmed: 24127442
J Clin Oncol. 2018 Sep 10;36(26):2684-2692
pubmed: 30024784
Haematologica. 1999 Oct;84(10):937-45
pubmed: 10509043
Haematologica. 2004 Aug;89(8):950-6
pubmed: 15339678
J Clin Oncol. 2015 Nov 1;33(31):3641-9
pubmed: 26304885
J Intern Med. 2019 Apr;285(4):407-418
pubmed: 30372796
Lancet Haematol. 2015 Oct;2(10):e427-36
pubmed: 26686044
Blood. 2019 Mar 28;133(13):1457-1464
pubmed: 30630862
Blood. 2005 Jul 1;106(1):27-34
pubmed: 15761020
Blood. 2010 Jul 22;116(3):354-65
pubmed: 20385793
J Clin Oncol. 2008 Oct 10;26(29):4791-7
pubmed: 18695255
Haematologica. 2020 Jan;105(1):e13-e16
pubmed: 31097634
J Clin Oncol. 1998 Mar;16(3):872-81
pubmed: 9508168
Lancet Oncol. 2017 Jan;18(1):100-111
pubmed: 27923552
Haematologica. 2010 Oct;95(10):1754-61
pubmed: 20494931
Leukemia. 2006 Oct;20(10):1723-30
pubmed: 16932345

Auteurs

Safaa M Ramadan (SM)

EORTC Headquarter, 1200 Brussels, Belgium.
Currently in the Hemato-oncology Division, European Institute of Oncology, 20141 Milan, Italy.
Currently in the Department of Medical Oncology, NCI-Cairo University, 11796 Cairo, Egypt.

Stefan Suciu (S)

EORTC Headquarter, 1200 Brussels, Belgium.

Marian J P L Stevens-Kroef (MJPL)

Department of Human Genetics, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands.

Roelof Willemze (R)

Hematology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.

Sergio Amadori (S)

Hematology, University Tor Vergata, 00133 Rome, Italy.

Theo de Witte (T)

Department of Hematology, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands.

Bob Löwenberg (B)

Hematology, Erasmus University Medical Center Rotterdam, 3000CA Rotterdam, The Netherlands.

Petra Muus (P)

Department of Hematology, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands.
Department of Hematology, Kings College Hospital, London SE5 9RS, UK.

Boris Labar (B)

Department of Hematology, University Hospital Center Rebro, 10000 Zagreb, Croatia.

Liv Meert (L)

EORTC Headquarter, 1200 Brussels, Belgium.

Gaetan de Schaetzen (G)

EORTC Headquarter, 1200 Brussels, Belgium.

Giovanna Meloni (G)

Department of Cellular Biotechnologies and Hematology, Sapienza University, 00161 Rome, Italy.

Giuseppe Leone (G)

Istituto di Ematologia, Università Cattolica S. Cuore, 00168 Rome, Italy.

Marco Vignetti (M)

Data Center and Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), 00182 Rome, Italy.

Jean-Pierre Marie (JP)

Department Hematology and Tumor Bank, Saint-Antoine Hospital, AP-HP & University Pierre & Marie Curie, 75571 Paris, France.

Michael Lübbert (M)

Department of Hematology, Oncology and Stem Cell Transplantation, Freiburg University Medical Center, Faculty of Medicine, 79106 Freiburg, Germany.

Frédéric Baron (F)

GIGA-I3, Hematology, University of Liège, 4000 Liège, Belgium.
Hematology, CHU of Liège, 4000 Liège, Belgium.

Classifications MeSH